

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2007 (27.12.2007)

PCT

(10) International Publication Number
WO 2007/147217 A1

(51) International Patent Classification:

C07D 215/28 (2006.01) A61K 31/47 (2006.01)
C07D 241/42 (2006.01) A61K 31/517 (2006.01)
C07D 239/88 (2006.01) A61P 35/04 (2006.01)

(21) International Application Number:

PCT/AU2007/000876

(22) International Filing Date: 22 June 2007 (22.06.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/815,779 22 June 2006 (22.06.2006) US

(71) Applicant (for all designated States except US): **PRANA BIOTECHNOLOGY LIMITED** [AU/AU]; Level 2, 369 Royal Parade, Parkville, Victoria 3052 (AU).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BUSH, Ashley** [AU/AU]; Level 2, 369 Royal Parade, Parkville, Victoria 3052 (AU).

(74) Agent: **GRIFFITH HACK**; 509 St Kilda Road, Melbourne, Victoria 3004 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR

(57) Abstract: The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis of glioma brain tumours and related conditions. The therapeutic agent comprises two fused 6- membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8.



WO 2007/147217 A1

- 1 -

METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR

BACKGROUND

5

FIELD

The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis glioma brain tumours and related conditions.

10

DESCRIPTION OF THE PRIOR ART

Cancer is a significant human health problem throughout the world and is one of the largest single causes of mortality and morbidity. The term "cancer" describes an array of different diseases linked by cumulative multiple genetic mutations, which result in the activation of oncogenes and/or the inactivation of tumor suppressor genes. The cause and source of these mutations differs between different cancers of human body organs.

15

Cancer within the human brain constitutes a very specific, serious and commonly terminal disease, with a median survival in patients of less than 1 year, despite provision of the optimal treatment available. The very unique biological environment of the brain, as separated by the blood brain barrier (BBB), significantly contributes to a range of site-specific cancers in this organ that require alternative treatment than those cancers of the remaining human body.

20

Approximately 17,000 primary brain tumors are diagnosed in patients in the United States alone each year. Of these, approximately 60% are glioma tumors or 'astrocytomas' that arise from brain cells called astrocytes or their precursors. Astrocytes are cells in the central nervous system that support neuronal function. Astrocytomas can be graded by histologic features that signify increasing malignancy into astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme (GBM). Anaplastic astrocytoma and GBM are considered high-grade gliomas while the astrocytoma is considered to be a low-grade

25

30

- 2 -

glioma. High-grade tumors grow rapidly and can easily infiltrate and spread through the brain. High-grade tumors are much more aggressive and require very intense therapy. The majority of astrocytic tumors in children are low-grade, whereas the majority in adults are high-grade. Astrocytomas can occur anywhere in the brain and spinal cord, however the majority are located in the cerebral hemispheres.

Patients with brain cancer most commonly present with seizures and a slowly progressive neurologic deficit, usually motor weakness. Alternatively, patients may present with generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment.

Although advances have been made in detection and therapy of brain cancer diseases, no universally successful method for prevention or treatment is currently available. Current therapies for many brain cancers are generally based on a combination of chemotherapy or surgery and radiation and continue to prove inadequate in many patients.

For example, the treatment of glioma brain tumours remains difficult in that no contemporary treatments are curative. Treatments are non-curative primarily due to tumors being beyond the reach of local control when it is first detected clinically or radiographically. No significant advancements in the treatment of brain cancers have occurred in the past 25 years. Without therapy, patients with GBMs uniformly die within 3 months. Patients conversely treated with optimal therapy, including surgical resection, radiation therapy, and chemotherapy, have a median survival of approximately 1 year. Therefore, the treatment of patients with brain cancer is often palliative and encompasses and/or surgery, radiotherapy, and chemotherapy.

Radiation therapy in addition to surgery has been shown to prolong survival in patients with brain cancers compared to surgery alone, however the responsiveness of these cancers to radiotherapy varies. In many instances, radiotherapy can induce a phase of remission, often marked with stability or regression of neurologic deficits as well as diminution in the size of the contrast-enhancing mass. Unfortunately, any period of response is often short-lived in brain cancer because the tumor typically recurs within 1 year, resulting in further clinical deterioration.

Chemotherapeutic regimens for brain cancer have suggested that fewer than 25% of patients obtain a significant survival benefit from adjuvant chemotherapy. Carmustine

- 3 -

(BCNU) and *cis*-platinum (cisplatin) have been the primary chemotherapeutic compounds used against malignant gliomas. All agents in use have no greater than a 30-40% response rate, and most fall into the range of 10-20%. A major hindrance to the use of chemotherapeutic compounds for brain tumours is the fact that the BBB effectively
5 excludes many agents from the CNS. Despite initial attempts investigating the delivery of chemotherapeutic compounds *via* an intraarterial route rather than intravenously, no survival advantage has been observed.

The extent of surgery (biopsy versus resection) has been shown in a number of studies to affect length of survival. For example, patients with high-grade gliomas who had
10 a gross total resection had a 2-year survival rate of 19%, while those with a subtotal resection had a 2-year survival rate of 0%.

As many brain cancers cannot be cured with surgery, the surgical goals are to establish a pathological diagnosis, relieve mass effect, and, if possible, achieve a gross total resection to facilitate adjuvant therapy.

15 Stereotactic biopsy followed by radiation therapy has been considered in certain circumstances. These include patients with a tumor located in an eloquent area of the brain; patients whose tumors have minimal mass effect or are infiltrating without discrete margins; and patients in poor medical condition, precluding general anesthesia. Median survival after stereotactic biopsy and radiation therapy is reported to be from 27-47 weeks.

20 In light of the foregoing, new approaches for the management of glioblastomas and other glioma brain tumours are critically necessary.

SUMMARY

25 The present invention is predicated in part on the determination that particular agents are effective in inhibiting the development of glioma brain tumours and related conditions in humans. Hence, the present invention contemplates the use of an agent which comprises a compound having two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxy at position 8 to reduce the growth of glioma brain tumours and in
30 particular glioblastomas (GBM) in human subjects. The present invention is particularly useful for treating or preventing or otherwise reducing the risk of development of GBM, however, the present invention extends to the treatment of any glioma brain tumour


- 4 -

including astrocytomas, anaplastic astrocytoma, mixed glioma, oligodendroglioma and other gliomas.

The agent of the present invention may possess one or more of the following properties: crosses the BBB, exhibits reduced adverse side affects; stable in aqueous environments; selectively cytotoxic to cancer cells; and exhibits reduced cytotoxicity to non-malignant cells. Preferably, the agent has two or more, three or more or four or more or five or more of the above-listed properties. In addition, the agent may be selected on the basis that it acts synergistically with another agent such as a chemotherapeutic, immunological or cytokine agent.

Useful agents comprise compounds of the formula (I) which are described in detail below.

In a first aspect there is provided a method for the treatment, amelioration and/or prophylaxis of a glioma brain tumour which comprises administration of an effective amount of an agent which comprises a compound of formula (I):



in which

R² is H; optionally substituted C₁₋₆ alkyl; optionally substituted C₂₋₆ alkenyl; optionally substituted C₂₋₆ alkynyl; optionally substituted C₃₋₆ cycloalkyl; optionally substituted aryl; optionally substituted heterocyclyl; CN; OR⁶, SR⁶, COR⁶, CSR⁶, HCNOR⁶ or HCNNR⁶ in which R⁶ is H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; NR⁸R⁹ or SO₂NR⁸R⁹ in which R⁸ and R⁹ are independently selected from H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl and optionally substituted heterocyclyl; CONR⁹R¹⁰ in which R⁹ is as defined above and R¹⁰ is optionally substituted

- 5 -

C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; CH₂CONR⁸R⁹ in which R⁸ and R⁹ are as defined above; and (CH₂)NR⁹R¹¹ in which R⁹ is as defined above and R¹¹ is selected from optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and SO₂R¹² in which R¹² is optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl or optionally substituted heterocycl and n is 1 to 6;

R³ is selected from H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl, optionally substituted heterocycl, optionally substituted C₁₋₆ alkoxy, optionally substituted acyl, hydroxy, optionally substituted amino, optionally substituted thio, optionally substituted sulphonyl, optionally substituted sulphinyl, optionally substituted sulphonylamino, halo, SO₃H, amine, CN, CF₃ and halo.

X is CH or N;

Y is CH, CO, CS or N; and

q is 1, 2 or 3,

salts, hydrates, solvates, derivatives, pro-drugs, tautomers and/or isomers thereof

to a subject in need thereof.

The present invention particularly extends to glioma forms of brain tumours such as astrocytoma, GBM, anaplastic astrocytoma, mixed glioma and oligodendroglioma.

Of the gliomas, GBM is particularly treatable with the agents disclosed herein. A defined or specific dosage amount may be administered.

There is also provided a specific dosage range to inhibit growth or viability of cells associated with a glioma in the brain. The dosage range includes from about 1 ng to about 1g per subject per administration. The administration may be a single dose or a series of divided doses.

There is further provided use of an agent which comprises the compound of formula (I) defined above in the manufacture of a medicament for the treatment, amelioration and/or prophylaxis of a glioma brain tumour.

There is still further provided use of an agent which comprises the compound of

- 6 -

formula (I) defined above for the treatment, amelioration and/or prophylaxis of a glioma brain tumour.

Combination therapy also forms part of the present invention in which two or more agents are administered or an agent and another active such as a chemotherapeutic compound, a cytokine, genetic molecule, an anti-oxidant and/or an anesthetic.

Reference to a "chemotherapeutic compound" includes a chemical compound, immunological compound, natural product or sRNAi complex or a product of an introduced viral vector.

Although, the preferred subject is a human, the present invention has application in the veterinary and animal husbandry industries and hence extends to non-human animals.

In a second aspect, there is provided a formulation comprising an agent which comprises the compound of formula (I) defined above for treating, ameliorating and/or preventing a glioma brain tumour.

BRIEF DESCRIPTION OF FIGURES

Fig. 1 is a graph showing the brain and plasma concentrations of compounds following IV administration to Swiss Outbred mice at a nominal does of 5mg/kg. Data is presented as mean 1SD(n=3). The compounds are designated by letter and are defined in the specification.

Fig. 2 is a graph showing a cytotoxicity screen of compounds on C6 cells. The compounds tested are designated by letter and are defined in the specification.

Fig. 3 is a graphical representation showing a cytotoxicity screen of different agents on U87MG cells. The compounds tested are designated by letter and are defined in the specification.

Fig. 4 is a graph showing a cytotoxicity screen of compounds on SMA 560 cells. The compounds tested are designated by letter and are defined in the specification.

Fig. 5 is a graph showing a cytotoxicity screen of compounds on 3T3 cells. The

- 7 -

compounds tested are designated by letter and are defined in the specification.


Figs. 6a to d are graphs showing effects of compounds A, B, S and H in the C6 glioma model (a,c) and the SMA560 glioma model (b,d).

- 8 -

DETAILED DESCRIPTION

Compounds

The compound of formula (I) is preferably a compound of formula (I'):



in which

R^2 is H; optionally substituted C_{1-6} alkyl; optionally substituted C_{2-6} alkenyl; optionally substituted C_{2-6} alkynyl; optionally substituted C_{3-6} cycloalkyl; optionally substituted aryl; optionally substituted heterocyclyl; CN; OR^6 , SR^6 , COR^6 , CSR^6 , $HCNOR^6$ or $HCNNR^6$ in which R^6 is H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; NR^8R^9 or $SO_2NR^8R^9$ in which R^8 and R^9 are independently selected from H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl and optionally substituted heterocyclyl; $CONR^9R^{10}$ in which R^9 is as defined above and R^{10} is optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; $CH_2CONR^8R^9$ in which R^8 and R^9 are as defined above; and $(CH_2)NR^9R^{11}$ in which R^9 is as defined above and R^{11} is selected from optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and SO_2R^{12} in which R^{12} is optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl and n is 1 to 6;

- 9 -

R^5 and R^7 are independently selected from H, optionally substituted C_{1-6} alkyl and halo;


X is CH or N;

Y is CH, CO, CS or N; and

5 q is 1, 2 or 3.

The compounds of formula (I') include those in which X and Y are CH; the X at the 3 position is N, the X at the 6 position is CH and the other X is CH and Y is CO or CS; the X at the 3 and 6 positions is CH and the other X is N and Y is CO; X is CH and Y is N; Y and X at position 3 are CH; X at position 6 is N and the other X is C.

10 In one embodiment, the compound of formula (I') has the formula (IA):



in which

R^2 , R^5 , R^7 , R^8 and q are as defined above.

R^2 is preferably located at either the 2 or 3 positions or both and is selected from H; optionally substituted C_{1-4} alkyl; optionally substituted C_{2-4} alkenyl; optionally substituted C_{3-6} cycloalkyl; optionally substituted 6-membered aryl optionally condensed with an optionally substituted 6 membered aryl or heteroaryl; optionally substituted saturated or unsaturated 5- or 6-membered N-containing heterocyclyl optionally condensed with an optionally substituted 6-membered aryl or heteroaryl; $(CH_2)_n R^{13}$ in which n is as defined above and R^{13} is optionally substituted C_{1-4} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted saturated or unsaturated 5- or 6-membered N-containing heterocyclyl or optionally substituted 6-membered aryl; $NR^{14}R^{15}$ in which R^{14} and R^{15} are independently selected from H, optionally substituted C_{1-4} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted saturated or unsaturated 5-or 6-membered N-containing heterocyclyl and optionally substituted 6-membered aryl; $HCNOR^{16}$ in which R^{16} is H,


- 10 -

optionally substituted C_{1-4} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted membered saturated or unsaturated 5- or 6- N-containing heterocyclyl or optionally substituted 6-membered aryl; $CH_2CONR^{17}R^{18}$ in which R^{17} and R^{18} are independently selected from H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl and optionally substituted 5 or 6-membered N-containing heterocyclyl optionally condensed with optionally substituted 6- membered aryl; and $(CH_2)_nNR^{19}R^{20}$ in which R^{19} and R^{20} are independently selected from optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl and SO_2R^{21} in which R^{21} is selected from optionally substituted C_{1-6} alkyl and optionally substituted 6-membered aryl and n is as defined above.

More preferably R^2 is H, optionally substituted C_{1-4} alkyl or $(CH_2)_nNR^{19}R^{20}$ in which n, R^{19} and R^{20} are as defined above.

Preferably R^5 and R^7 are both halo, more preferably both are chloro or one is chloro and the other is iodo.

A subclass of compounds of formula (IA) have the formula (Ia):



(Ia)

in which


R^2 , R^5 and R^7 are as defined above.

Subclasses of compounds of the formula (Ia) are as follows:

- 11 -

(i)

5




10 in which

R^2 is selected from H or optionally substituted saturated or unsaturated 6-membered N-containing heterocycyl such as pyridyl; and

R^7 is Cl or I.


Representative examples are shown below:

15



Compound A


20



Compound ZA

(ii)

25




in which


30 R^{19} and R^{20} are independently selected from H and optionally substituted C_{1-6} alkyl.

- 12 -


Representative examples are shown below:




Compound B




Compound D



Compound G



Compound J



Compound K


5

10

15

- 13 -

(iii)




in which


 R^9 is H; and

- 5 R^{10} is selected from optionally substituted C_{1-6} alkyl, more preferably C_{1-6} alkyl optionally substituted with an unsaturated 5-membered N-containing heterocycyl such as an imidazolyl.

Representative examples are shown below:




Compound C



Compound E

- 14 -


(iv)




in which

- 10 R^8 and R^9 are independently selected from H, optionally substituted C_{1-6} alkyl and an optionally substituted saturated or unsaturated 5- or 6- membered N-containing heterocyclyl such as pyridinyl.

A representative example is shown below:



(v)





in which


- 30 R^{16} is H or optionally substituted C_{1-6} , preferably C_{1-4} alkyl.

Representative examples are shown below:

- 15 -



In another embodiment, the compound of formula (I') has the formula (IB):



in which

R^2 , R^5 , R^7 , R^8 and Y are as defined above; and

r is 1 or 2.

R^2 is preferably located at either the 2 or 3 positions or both and is selected from H; optionally substituted C_{1-4} alkyl; optionally substituted C_{1-4} alkenyl; optionally substituted C_{3-6} cycloalkyl; optionally substituted 6-membered aryl optionally condensed with an optionally substituted 6 membered aryl or heteroaryl; optionally substituted saturated or unsaturated 5- or 6-membered N-containing heterocyclyl optionally condensed with an optionally substituted 6-membered aryl or heteroaryl; $(CH_2)_n R^{13}$ in which n is as defined above and R^{13} is optionally substituted C_{1-4} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted saturated or unsaturated 5- or 6-membered N-containing heterocyclyl or optionally substituted 6-membered aryl; $NR^{14}R^{15}$ in which R^{14} and R^{15} are independently selected from H, optionally substituted C_{1-4} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted saturated or unsaturated 5-or 6-membered N-containing heterocyclyl and optionally substituted 6-membered aryl; $NHCOR^{16}$ in which R^{16} is optionally substituted C_{1-4} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted membered saturated or unsaturated 5- or 6- N-containing heterocyclyl or


- 16 -

optionally substituted 6-membered aryl; $\text{CH}_2\text{CONR}^{17}\text{R}^{18}$ in which R^{17} and R^{18} are independently selected from H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl and optionally substituted 5 or 6-membered N-containing heterocyclyl optionally condensed with optionally substituted 6-membered aryl; and $(\text{CH}_2)_n\text{NR}^{19}\text{R}^{20}$ in which R^{19} and R^{20} are independently selected from optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl and SO_2R^{21} in which R^{21} is selected from optionally substituted C_{1-6} alkyl and optionally substituted 6-membered aryl and n is as defined above,

More preferably R^2 is selected from optionally substituted C_{1-4} alkyl; optionally substituted C_{1-4} alkenyl; an optionally substituted saturated or unsaturated 5- or 6-membered N-containing heterocyclyl optionally condensed with an optionally substituted 6-membered aryl or heteroaryl; $(\text{CH}_2)_n\text{R}^{13}$ in which n is 1 to 3 and R^{13} is optionally substituted C_{3-6} cycloalkyl or an optionally substituted saturated or unsaturated 5- or 6-membered N-containing heterocyclyl; $\text{NR}^{14}\text{R}^{15}$ in which R^{14} is H and R^{15} is H or optionally substituted C_{1-4} alkyl or optionally substituted 6-membered aryl; NHCOR^{16} in which R^{16} is optionally substituted C_{1-4} alkyl or optionally substituted 6-membered aryl.

Preferably R^5 is H or chloro and R^7 is chloro or iodo.

A subclass of compounds of formula (IB) have the formula (Ib)




(Ib)

in which

R^2 , R^5 , R^7 , Y and q are as defined above.

Subclasses of compounds of the formula (Ib) are as follows:

- 17 -



in which


R^2 is selected from optionally substituted C_{1-6} alkyl and optionally substituted C_{3-6} cycloalkyl;

R^5 is Cl or H;


R^7 is Cl or I; and

Y is CO or CS.


Representative examples are as follows:



Compound F




Compound P




Compound R

- 18 -




Compound Z




in which

 R^5 and R^7 are as defined above; and R^{13} is as defined above, preferably optionally substituted C_{3-6} cycloalkyl or optionally substituted 5- or 6- membered heterocyclyl such as pyridinyl, thiazolyl or isoxazolyl.


Representative examples are as follows:



Compound H




Compound I




Compound N


- 19 -



Compound O




Compound U




in which

R^{14} and R^{15} are as defined above, preferably independently selected from H and optionally substituted 6-membered aryl such as phenyl substituted with halo.

A representative example is as follows:



Compound Q




- 20 -

in which


R^2 is selected from optionally substituted C_{1-6} alkyl, $CH_2NR^9R^{11}$ in which R^9 is H and R^{11} is optionally substituted C_{1-6} alkyl.

A representative example is shown below:



Compound T

In another embodiment, the compound of formula (I') has the formula (IC):



in which


R^2 , R^5 , R^7 and r are as defined above.

R^2 is preferably located at the 3 position and is selected from H, optionally substituted

C_{1-4} alkyl and $CONR^9R^{10}$ in which R^9 and R^{10} are as defined above, preferably R^8 is H and R^7 is chloro or iodo.

A subclass of compounds of formula (IC) have the formula (Ic):


- 21 -



(Ic)

in which R^2 , R^5 and R^7 are as defined above.

Subclasses of compounds of the formula (Ic) are as follows:




5

in which R^2 is optionally substituted C_{1-6} alkyl; and
 R^7 is as defined above, preferably H or I.


Representative examples are shown below:

10




Compound V

15




Compound W


- 22 -



Compound X




Compound S



in which

- 10 R^7 is as defined above, preferably I;
 R^9 is H; and
 R^{10} is optionally substituted C_{1-6} alkyl.


A representative example is shown below:



Compound Y

In another embodiment, the compound of the formula (I') has the formula (ID):


- 23 -



in which

R^2 , R^5 , R^6 and r are as defined above.

5 A subclass of compounds of the formula (ID) have the formula (Id):




in which

10 R^2 , R^5 , R^6 and R^7 are as defined above.

R^2 is preferably optionally substituted C_{1-6} alkyl and R^5 and R^7 are both chloro.

A representative example is as follows:




Compound M

15

In another embodiment, the compound of formula (I') has the formula (IE):

- 24 -




(IE)

in which

R^2 , R^5 and q are as defined above.

A subclass of compounds of formula (IE) have the formula (Ie):




(Ie)

in which

R^2 is as defined above; and

R^7 is optionally substituted C_{1-6} alkyl.

A representative example is as follows:



Compound L

The terms " C_{1-6} alkyl" or " C_{1-4} alkyl" used either alone or in compound words such as "optionally substituted C_{1-4} alkyl" refers to straight chain or branched chain hydrocarbon groups having from 1 to 6 and 1 to 4 carbon atoms, respectively. Illustrative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl or hexyl, preferably methyl, ethyl or propyl.

The term " $(CH_2)_n$ " as used herein include both linear and branched chains.

- 25 -

The term "C₂₋₆ alkenyl" refers to straight chain or branched chain hydrocarbon groups having at least one double bond of either E or Z stereochemistry where applicable and 2 to 6 carbon atoms. Examples include vinyl, 1-propenyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

5 The term "C₂₋₆ alkynyl" used either alone or in compound words such as "optionally substituted C₂₋₆ alkynyl" refers to straight chain or branched chain hydrocarbon groups having from 2 to 6 carbon atoms and having in addition one triple bond. Illustrative of such groups are ethynyl, 1-propynyl, 1- and 2-butyne, 2-methyl-2-propynyl, 2-pentyne, 3-pentyne, 4-pentyne, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.

10 The term "C₃₋₆ cycloalkyl" used either alone or in compound words such as "optionally substituted C₃₋₆ cycloalkyl" refers to saturated carbocyclic groups having 3 to 6 carbon atoms. Illustrative of such groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, preferably cyclopropyl.

15 The term "heterocyclyl" refers to saturated or unsaturated, monocyclic or polycyclic hydrocarbon groups containing at least one heteroatom atom selected from the group consisting of nitrogen, sulphur and oxygen.

Suitable heterocyclic groups include N-containing heterocyclic groups, such as, unsaturated 5- or 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyridinyl, pyrimidinyl, 20 pyrazinyl, pyridazinyl, triazolyl or tetrazolyl;

saturated 5- or 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, such as, pyrrolidinyl, imidazolidinyl, piperidino or piperazinyl;

25 unsaturated condensed heterocyclic groups containing 1 to 5 nitrogen atoms, such as indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl or tetrazolopyridazinyl;

unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, such as, oxazolyl, isoxazolyl or oxadiazolyl;

saturated 5- or 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, such as, morpholinyl;

30 unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms and 1 to 3 nitrogen atoms, such as, thiazolyl or thiadiazolyl; and

saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms

- 26 -

and 1 to 3 nitrogen atoms, such as, thiazolidinyl.

Preferably the heterocyclyl is an unsaturated 5 or 6-membered heteromonocyclic group containing 1 to 3 nitrogen atoms such as pyrazolyl, pyridinyl, pyrimidinyl or imidazolyl; a saturated 5 or 6-membered heteromonocyclic group containing 1 to 4
5 nitrogen atoms such as pyrrolidinyl or piperazinyl; an unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms such as benzimidazolyl; a saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms such as morpholinyl; or an unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms and 1 to 3 oxygen atoms, such as thiazolyl.

10 The term "unsaturated or saturated 5- or 6-membered N-containing heterocyclyl group optionally condensed with an optionally substituted 6-membered aryl" used either alone or in compound words such as "optionally substituted unsaturated or saturated 5- or 6-membered N-containing heterocyclyl group optionally condensed with an optionally substituted 6-membered aryl" refers to monocyclic or polycyclic heterocyclic groups
15 containing at least one nitrogen atom and optionally other heteroatoms selected from sulphur and oxygen.

The term "aryl" refers to single, polynuclear, conjugated or fused residues of aromatic hydrocarbons. Examples include phenyl, biphenyl, terphenyl, quaterphenyl, naphthyl, tetrahydronaphthyl, anthracenyl, dihydroanthracenyl, benzanthracenyl,
20 dibenzanthracenyl and phenanthrenyl. A preferred aryl is phenyl.

The term "6-membered aryl" used either alone or in compound words such as "optionally substituted 6-membered aryl" denotes a 6-membered carbocyclic aromatic group. Illustrative of such aryl groups are phenyl. Preferably, the aryl is optionally substituted phenyl such as 4-halophenyl, more preferably 4-fluorophenyl.

25 The term "6-membered heteroaryl" used either alone or in compound words such as "optionally substituted 6-membered heteroaryl" denotes a 6-membered aromatic heterocycle containing one or more heteroatoms. Examples include pyridyl pyrazinyl, pyrimidinyl and pyridazinyl, each of which may be optionally substituted by methyl or methoxy.

30 The term "halo" refers to fluorine, chlorine, bromine or iodine, preferably fluorine, iodine or chlorine, more preferably chlorine or iodine.

The term "acyl" used either alone or in compound words such as "optionally

- 27 -

substituted acyl”, “aryl acyl” or “alkyl acyl”, denotes carbamoyl, aliphatic acyl group, acyl group containing an aromatic ring which is referred to as aromatic acyl or an acyl group containing a heterocyclic ring which is referred to as heterocyclic acyl having 1 to 20 carbon atoms, preferably 1 to 14 carbon atoms. Examples of acyl include carbamoyl;

5 straight chain or branched alkanoyl, such as, formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl or icosanoyl; alkoxycarbonyl, such as, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl or

10 heptyloxycarbonyl; cycloalkylcarbonyl, such as, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentyl, carbonyl or cyclohexylcarbonyl; alkylsulfonyl, such as, methylsulfonyl or ethylsulfonyl; alkoxysulfonyl, such as, methoxysulfonyl or ethoxysulfonyl; aroyl, such as, benzoyl, toluoyl or naphthoyl; aralkanoyl, such as, phenylalkanoyl, for example, phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutyl, phenylpentanoyl or

15 phenylhexanoyl or naphthylalkanoyl, for example, naphthylacetyl, naphthylpropanoyl or naphthylbutanoyl; aralkenoyl, such as, phenylalkenoyl, for example, phenylpropenoyl, phenylbutenoyl, phenylmethacrylyl, phenylpentenoyl or phenylhexenoyl or naphthylalkenoyl, for example, naphthylpropenoyl, naphthylbutenoyl or naphthylpentenoyl; aralkoxycarbonyl, such as, phenylalkoxycarbonyl, for example,

20 benzyloxycarbonyl; aryloxycarbonyl, such as, phenoxycarbonyl or naphthylloxycarbonyl, aryloxyalkanoyl, such as, phenoxyacetyl or phenoxypropionyl, arylcarbamoyl, such as, phenylcarbamoyl; arylthiocarbamoyl, such as, phenylthiocarbamoyl, arylglyoxyloyl, such as, phenylglyoxyloyl or naphthylglyoxyloyl; arylsulfonyl, such as, phenylsulfonyl or naphthylsulfonyl; heterocycliccarbonyl; heterocyclicalkanoyl, such as, thienylacetyl,

25 thienylpropanoyl, thienylbutanoyl, thienylpentanoyl, thienylhexanoyl, thiazolylacetyl, thiadiazolylacetyl or tetrazolylacetyl, heterocyclicalkenoyl, such as, heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl or heterocyclichexenoyl; or heterocyclicglyoxyloyl, such as, thiazolylglyoxyloyl or thienylglyoxyloyl.

The term “optionally substituted thio” refers to optional substituents such as

30 radicals containing a linear or branched alkyl of 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms, attached to a divalent sulphur atom. Examples of alkylthio radicals include methylthio, ethylthio, propylthio, butylthio and

- 28 -

hexylthio.

The term "optionally substituted sulfinyl" refers to optional substituents such as radicals containing a linear or branched alkyl radical, of 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms, attached to a divalent -S(=O)- radical. Examples include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl.

The term "optionally substituted sulfonyl" refers to optional substituents such as radicals containing a linear or branched alkyl radical of 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms, attached to a divalent -SO₂- radical. Examples include methylsulfonyl, ethylsulfonyl and propylsulfonyl.

The term "alkoxy" refers to straight chain or branched oxy-containing radicals preferably each having alkyl portions of 1 to about 6 carbon atoms. Examples of alkoxy include methoxy, ethoxy, propoxy, butoxy and *tert*-butoxy.

The term "optionally substituted" refers to a group that may or may not be further substituted with one or more groups selected from C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, heterocyclyl, halo, haloC₁₋₆alkyl, haloC₃₋₆cycloalkyl, haloC₂₋₆alkenyl, haloC₂₋₆alkynyl, haloaryl, haloheterocyclyl, hydroxy, C₁₋₆ alkoxy, C₂₋₆alkenyloxy, C₂₋₆alkynyloxy, aryloxy, heterocyclyloxy, carboxy, haloC₁₋₆alkoxy, haloC₂₋₆alkenyloxy, haloC₂₋₆alkynyloxy, haloaryloxy, nitro, nitroC₁₋₆alkyl, nitroC₂₋₆alkenyl, nitroaryl, nitroheterocyclyl, azido, amino, C₁₋₆alkylamino, C₂₋₆alkenylamino, C₂₋₆alkynylamino, arylamino, heterocyclamino acyl, C₁₋₆alkylacyl, C₂₋₆alkenylacyl, C₂₋₆alkynylacyl, arylacyl, heterocyclylacyl, acylamino, acyloxy, aldehydo, C₁₋₆alkylsulphonyl, arylsulphonyl, C₁₋₆alkylsulphonylamino, arylsulphonylamino, C₁₋₆alkylsulphonyloxy, arylsulphonyloxy, C₁₋₆alkylsulphenyl, C₂₋₆alkylsulphenyl, arylsulphenyl, carboalkoxy, carboaryloxy, mercapto, C₁₋₆alkylthio, arylthio, acylthio, cyano and the like. Preferably, the optional substituent is C₁₋₄ alkyl, halo C₁₋₄ alkyl, hydroxy, halo, C₁₋₄ alkoxy or C₁₋₄ alkylacyl.

Preferably the derivative is a "pharmaceutically acceptable derivative". By "pharmaceutically acceptable derivative" is meant any pharmaceutically acceptable salt, hydrate, ester, ether, amide, active metabolite, analogue, residue or any other compound which is not biologically or otherwise undesirable and induces the desired pharmacological and/or physiological effect.

The salts of the compounds of formula (I) are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall

- 29 -

within the scope of the present invention, since these are useful as intermediates in the preparation of pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts include salts of pharmaceutically acceptable cations such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium; acid addition
5 salts of pharmaceutically acceptable inorganic acids such as hydrochloric, orthophosphoric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic and hydrobromic acids; or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, trihalomethanesulphonic,
10 toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety.

The salts may be formed by conventional means, such as by reacting the free base
15 form of the compound with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.

In addition, some of the compounds of the present invention may form solvates
20 with water or common organic solvents. Such solvates are encompassed within the scope of the invention.

The term "pro-drug" refers to functional derivatives of the compound of formula (I) which are readily convertible *in vivo* into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives
25 are described, for example, in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985.

A prodrug may be a pharmacologically inactive derivative of the active compound that requires transformation within the body in order to release the active compound, and that has improved delivery properties over the active compound. The transformation *in vivo* may be, for example, as the result of some metabolic process, such as chemical or
30 enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality. In one embodiment, the 8-hydroxyl on the compounds of formula (I) may be blocked to form a prodrug, in particular an ester

- 30 -

prodrug. The 8-hydroxy represents a principal site of metabolism for the compounds: conjugation with glucuronic acid or sulphate gives a hydrophilic species ready to be excreted.

The term "tautomer" is used herein in its broadest sense to include compounds of formula (I) which are capable of existing in a state of equilibrium between two isomeric forms. Such compounds may differ in the bond connecting two atoms or groups and the position of these atoms or groups in the compound.

The term "isomer" is used herein in its broadest sense and includes structural, geometric and stereo isomers. As the compound of formula (I) may have one or more chiral centres, it is capable of existing in enantiomeric forms.

Included within the scope of this invention are compounds of the formula I to which at least one of a detectable label, an affinity tag and a photoreactive group is linked.

Methods of treatment, amelioration and/or prophylaxis

Agents which comprise the compound of formula (I) may be used in the treatment, amelioration and/or prophylaxis of a glioma brain tumour such as astrocytoma, GBM and anaplastic astrocytoma, mixed glioma and oligodendroglioma.

Reference to an "agent" includes combinations of two or more active agents. A "combination" also includes multi-part such as a two-part composition where the agents are provided separately and given or dispensed separately or admixed together prior to dispensation. For example, a multi-part pharmaceutical pack may have two or more agents separately maintained. Hence, this aspect of the present invention includes combination therapy. Combination therapy includes the co-administration of an agent and another active such as a chemotherapeutic compound, a cytokine, genetic molecule and/or an anesthetic.

The terms "effective amount" and "therapeutically effective amount" of an agent as used herein mean a sufficient amount of the agent to provide the desired therapeutic or physiological or effect or outcome. Such an effect or outcome includes inhibiting the growth or viability of cells associated with a glioma in the brain. Undesirable effects, e.g. side effects, are sometimes manifested along with the desired therapeutic effect; hence, a practitioner balances the potential benefits against the potential risks in determining what is an appropriate "effective amount". The exact amount required will vary from subject to

- 31 -

subject, depending on the species, age and general condition of the subject, mode of administration and the like. Thus, it may not be possible to specify an exact "effective amount". However, an appropriate "effective amount" in any individual case may be determined by one of ordinary skill in the art using only routine experimentation.

5 The effective amount is deemed the amount required to inhibit the growth or viability of cells associated with a glioma. Effective amounts include from about 1 ng to about 1 g/subject administration. The administration may be a single dose or a series of divided doses. Amounts include from about 5 ng to about 800 mg/subject administration. Actual amounts include about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
10 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 ng or 200, 300, 400, 500, 600, 700, 800, 900, 1000 ng or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
15 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 mg or 200, 300, 400, 500, 600, 700, 800, 900, 1000 mg per patient.

"Treating" a subject may involve modulating or ameliorating growth of a glioma
20 brain tumour in an affected subject as well as treatment of a clinically a symptomatic subject having biochemical or immunological markers of a possible or developing glioma brain tumour, to the benefit of the subject. In one particular embodiment, the present invention contemplates a reduction of the growth or viability of cells associated with a glioma.

25 Reference to a "brain tumour" includes a brain cancer. The term "tumor" and "cancer" may be used interchangeably herein. Reference to a "glioma" includes GMB, astrocytoma, anaplastic astrocytoma, mixed glioma, oligodendroglioma or related brain cancers.

30 The "subject" as used herein refers to an animal, preferably a mammal and more preferably a primate including a lower primate and even more preferably a human who can benefit from the formulations and methods of the present invention. A subject regardless of whether a human or non-human animal may be referred to as an individual, patient,

- 32 -

animal, host or recipient. The agents and methods of the present invention have applications in human medicine, veterinary medicine as well as in general, domestic or wild animal husbandry. For convenience, an "animal" includes an avian species such as a poultry bird (including ducks, chicken, turkeys and geese), an aviary bird or game bird.

5 The condition in a non-human animal may not be a naturally occurring but induced such as in an animal model.

As indicated above, the preferred animals are humans, non-human primates such as marmosets, baboons, orangutan's, lower primates such as tupia, livestock animals, laboratory test animals, companion animals or captive wild animals. A human is the most
10 preferred target. However, non-human animal models may be used.

Examples of laboratory test animals include mice, rats, rabbits, guinea pigs and hamsters. Rabbits and rodent animals, such as rats and mice, provide a convenient test system or animal model as do primates and lower primates. Livestock animals include sheep, cows, pigs, goats, horses and donkeys. Non-mammalian animals such as avian
15 species, zebrafish, amphibians (including cane toads) and *Drosophila* species such as *Drosophila melanogaster* are also contemplated. Instead of a live animal model, a test system may also comprise a tissue culture system.

Pharmaceutical Formulations

20 The formulations of the present invention comprise at least one of the compounds of formula (I) together with one or more pharmaceutically acceptable carriers and optionally other therapeutic agents. Each carrier must be pharmaceutically "acceptable" in the sense of being compatible with the other ingredients of the formulations and not injurious to the subject. Carriers may include excipients and other additives such as
25 diluents, detergents, coloring agents, wetting or emulsifying agents, pH buffering agents, preservatives, and the like. Formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by methods well
30 known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into

- 33 -

association the active ingredient with liquid carriers, diluents, adjuvants and/or excipients or finely divided solid carriers or both, and then if necessary shaping the product.

The compounds of formula (I) may be administered orally, topically, or parenterally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes subcutaneous injections, aerosol for administration to lungs or nasal cavity, intravenous, intramuscular, intrathecal, intracranial, injection, intraocular or infusion techniques.

The present invention also provides suitable topical, oral, and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention. The compounds of the present invention may be administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders, granules, emulsions, capsules, syrups or elixirs. The formulations for oral use may contain one or more agents selected from the group of sweetening agents, flavoring agents, colouring agents and preserving agents in order to produce pharmaceutically elegant and palatable preparations. Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharin. Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar. Suitable flavoring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavoring. Suitable preservatives include sodium benzoate, vitamin E, alphanatocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate. The tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.

These excipients may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents, such as corn starch or alginic acid; (3) binding agents, such as starch, gelatin or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc. These tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be

- 34 -

employed. Coating may also be performed using techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

The above compounds as well as the pharmaceutically-active agent useful in the method of the invention can be administered, for *in vivo* application, parenterally by injection or by gradual perfusion over time independently or together. Administration may be intra-ocular, intravenously, intraarterial, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally or infusion by, for example, osmotic pump. For *in vitro* studies the agents may be added or dissolved in an appropriate biologically acceptable buffer and added to a cell or tissue.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, anti-microbials, anti-oxidants, attenuating agents, growth factors and inert gases and the like.

The present invention includes various pharmaceutical formulations useful for ameliorating disease. The pharmaceutical formulations according to one embodiment of the invention are prepared by bringing an above compound, analogs, derivatives or salts thereof, or combinations of the above compounds and one or more pharmaceutically-active agents into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial, anti-oxidants, attenuating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts,

- 35 -

preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 20th ed. Williams and Wilkins (2000) and The British National Formulary 43rd ed. (British Medical Association and Royal Pharmaceutical Society of Great Britain, 2002; <http://bnf.rhn.net>), the contents of which are hereby incorporated by
5 reference. The pH and exact concentration of the various components of the pharmaceutical formulations are adjusted according to routine skills in the art. See Goodman and Gilman's The Pharmacological Basis for Therapeutics (7th ed., 1985).

The pharmaceutical formulations are preferably prepared and administered in dose units. Solid dose units may be tablets, capsules and suppositories. For treatment of a
10 subject, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the subject, different daily doses can be used. Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and
15 also by multiple administration of subdivided doses at specific intervals.

The pharmaceutical formulations according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the subject. Typically, dosages used *in vitro* may provide useful guidance in the amounts
20 useful for *in situ* administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of the cytotoxic side effects. Various considerations are described, e.g., in Langer, *Science*, 249:1527, 1990.

Formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate,
25 calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.

Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspension. Such excipients may be (1)
30 suspending agent such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; (2) dispersing or wetting agents which may be (a) naturally occurring

- 36 -

phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; (c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylenoxycetanol; (d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and
5 hexitol such as polyoxyethylene sorbitol monooleate, or (e) a condensation product of ethylene oxide with a partial ester derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate.

The pharmaceutical formulations may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to known
10 methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In
15 addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The above compounds may also be administered in the form of liposome delivery
20 systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

The above compounds may also be presented for use in the form of veterinary formulations, which may be prepared, for example, by methods that are conventional in the
25 art. Examples of such veterinary formulations include those adapted for:

(a) oral administration, external application, for example drenches (e.g. aqueous or non-aqueous solutions or suspensions); tablets or boluses; powders, granules or pellets for admixture with feed stuffs; pastes for application to the tongue;

(b) parenteral administration for example by subcutaneous, intramuscular or
30 intravenous injection, e.g. as a sterile solution or suspension; or (when appropriate) by intramammary injection where a suspension or solution is introduced in the udder *via* the teat;

- 37 -

(c) topical applications, e.g. as a cream, ointment or spray applied to the skin;
or

(d) intravaginally, e.g. as a pessary, cream or foam.

The present invention is further described by the following non-limiting Examples.

- 38 -

EXAMPLE 1***Assessment of Compounds***

The following Assays were used in the assessment of the compounds for suitability for use
5 in the methods of the present invention.

Assay 1. Neurotoxicity Assays***Primary cortical neuronal cultures***

Cortical cultures were prepared as previously described (White *et al.*, *J Neuroscience*
10 18:6207-6217, 1998). Embryonic day 14 BL6Jx129sv mouse cortices were removed,
dissected free of meninges and dissociated in 0.025% (wt/vol) trypsin. Dissociated cells
were plated in 48 well culture plates at a density of 2×10^6 cells/mL in MEM with 25%
(vol/vol) FCS and 5% (vol/vol) HS and incubated at 37°C, 2hrs. Media was then replaced
with Neurobasal media (Invitrogen Life Technologies) and B27 supplements (Invitrogen
15 Life Technologies). Cultures were maintained at 37°C in 5% CO₂. Prior to
experimentation, the culture medium was replaced with Neurobasal media and B27 minus
antioxidants (Invitrogen Life Technologies).

(a) MTS Assay for Cell Viability

20 Cell viability is determined using the MTS assay. Culture medium is replaced with fresh
neurobasal medium plus B27 supplements minus antioxidants. 1/10th volume MTS
solution (Cell Titre 96 Aqueous One, Promega Corporation) and incubated at 37°C,
2hrs. 200 microlitre aliquots are measured with a spectrophotometer at 560 nm.

(b) Assay for Test Compound Cytotoxicity

25 Neuronal cortical cells were cultured for five days as per Assay 2 in NB media and B27
supplement.

On day six the test compounds were added to the neuronal cell cultures in NB media and
30 B27 supplement minus antioxidants.

- 39 -

Test compounds were dissolved in 100% DMSO to a concentration of 2.5 mM (10mM if excess compound was weighed out per vial – then diluted to 2.5mM). 2.5mM stock solution was serially diluted 1 in 10 to give working solutions of 250µM, 25µM, 2.5µM. Test compounds were not added directly to cells, instead they were added to a 48 well

5 'Drug Plate' as comprised below:

Preparation of "Drug Plate":

To a 48 well plate add:

- Well 1: 576 ul NB+B27(no antioxidant)* + 24 µl 2.5µM test compound
- 10 Well 2 : 576 ul NB+B27(no antioxidant) + 24 µl 25µM test compound
- Well 3 : 576 ul NB+B27(no antioxidant) + 24 µl 250µM test compound
- Well 4 : 576 ul NB+B27(no antioxidant) + 24 µl 2.5µM test compound
- Well 5 : 576 ul NB+B27(no antioxidant) + 24 µl 25µM test compound
- Well 6 : 576 ul NB+B27(no antioxidant) + 24 µl 250µM test compound
- 15 Well 7 : 576 ul NB+B27(no antioxidant) + 24 µl test compound diluent**
- Well 8 : 600 ul NB+B27(no antioxidant)

The Drug Plate was incubated at 37° C for 15 mins. 200 µl of each well was added in triplicate to the corresponding cell plate. The cell plate was incubated at 37 C, for 4 days.

20

* NB media and B27 (no antioxidants) ,

** PBT diluent 10% DMSO in NB+B27 (no antioxidants)

On completion of the assay, 1/10 volume MTS was added per well of plate (i.e. 25µl/ 250 µl). The plates were incubated at 37C for 2hrs, and then absorbance was read at 560nm.

25

- 40 -

Assay 2. Solubility Assay

Stock solutions of test compounds (1mM) were prepared in dimethyl sulfoxide. Compounds which did not dissolve were classed as not soluble (N). The DMSO stock solutions were diluted 1 in 100 into PBS pH 7.4. Compounds which gave a clear solution were classed as soluble (Y), while those compounds which gave a translucent suspension after dissolution in DMSO were classed as “crashed out” (C).

Assay 3. Physiochemical Properties

Polar Surface Area Calculations (PSA)

Polar surface area values were calculated using the web-based program available through “Molinspiration”, a package for calculation of molecular properties.

Turbidimetric Solubility Measurements

The solubility estimate was measured at both pH 2.0 and pH 6.5. This is within the pH range that can be anticipated along the proximal gastrointestinal tract in humans.

The compounds were dissolved in DMSO to appropriate concentrations and then spiked into either 0.01M HCl (approximately pH = 2.0) or pH 6.5 isotonic phosphate buffer, the final DMSO concentration being 1%. Samples were then analysed *via* Nephelometry to determine a solubility range (Bevan and Lloyd, *Anal. Chem.* 72:1781-1787, 2000).

cLog P values

Theoretical Log P values were determined using the ACD Log P software. The values quoted have been calculated from an untrained database and refer to the unionised species.

E Log D

Effective Log D values were measured using a chromatographic method employing a SUPELCOSIL LC-ABZ column using an octanol saturated mobile phase at pH 7.4.

See F. Lombardo *et al*, J. Med. Chem. 2000, 43, 2922-2928.

Assay 4. Blood Brain Barrier Penetration

Each compound tested demonstrates a permeability across a healthy BBB.

5 A bolus injection of each of the test compound (50 μ L of a 3 mg/mL aqueous solution containing 40% propylene glycol and 10% ethanol) was administered by tail vein injection to male Swiss Outbred mice (5-7 weeks of age).

At 5 and 60 min post-dose (n=3 mice at each time point), blood was collected by cardiac puncture and the whole brain was removed by making an incision through the back of the skull. Mice were anaesthetised approximately 3-4 min prior to blood and brain harvest
10 with an intraperitoneal injection of ketamine and xylazine (133 mg/kg and 10 mg/kg, respectively).

The whole brain was placed into preweighed polypropylene vials and stored at -20°C until analysis. On the day of analysis, the whole brain was homogenised in 3 parts of water (on ice to reduce the potential for *ex vivo* brain degradation) and an aliquot of the brain
15 homogenate and plasma was analysed for compound concentration by LCMS. Standards were prepared by spiking blank brain homogenate and both samples and standards were processed by adding acetonitrile to the tissue homogenate, centrifuging and injecting an aliquot of the supernatant onto the LCMS.

To ensure complete recovery of compound from the brain, brain homogenate was spiked
20 with compound (in 50% acetonitrile: 50% water) to a nominal concentration of 500 ng/mL. The concentration of compound in the supernatant was then determined by LCMS and compared to the supernatant concentration when compound was added following precipitation with acetonitrile.

25 Calculations

$$C_{\text{brain}} = C_{\text{brain homogenate}} - C_{\text{brain vasculature}}$$

$$C_{\text{brain vasculature}} = C_{\text{plasma}} * V_p$$

$$B : P = \frac{C_{\text{brain}}}{C_{\text{plasma}}}$$

$$P_{\text{app}} \text{ (cm/s)} = \frac{C_{\text{brain}}}{\int_0^t C_{\text{plasma}} \cdot dt * A}$$

- 42 -

C_{brain} = concentration of compound in brain parenchyma (ng/g)

$C_{\text{brain homogenate}}$ = concentration of compound in brain homogenate (ng/g)

$C_{\text{brain vasculature}}$ = concentration of compound in brain vasculature (ng/g)

C_{plasma} = concentration of compound in plasma (ng/mL)

5 V_p = brain plasma volume (26 $\mu\text{L/g}$ for male Swiss Outbred mice)

B:P = brain-to-plasma ratio

P_{app} = apparent permeability coefficient of compound permeating the blood-brain barrier

$\int_0^t C_{\text{plasma}} \cdot dt$ = concentration of compound in plasma from time zero to 5 min post-dose

(equivalent to the 5 min post-dose plasma concentration, assuming no back diffusion from

10 brain to plasma within this time period)

A = surface area of capillaries forming the blood-brain barrier (240 cm^2/g brain weight for mouse)

The brain and plasma concentrations of compounds following IV administration to male

15 Swiss Outbred mice at a nominal dose of 5 mg/kg is shown in Fig. 1..Each compound tested demonstrates a level of permeability across a healthy BBB.

EXAMPLE 2

Properties of Compounds








20

The following table provides the properties and structures of compounds of the present invention.








25

30








- 43 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal</u> <u>cells:</u> 90, 77 <u>M17 cells:</u> 106.6, 72.7	305.5 33.1	4.32 (E) 1.85 (C) 2.17	none	Up to 700 ng/mL	0.20 at 5min, 0.17 at 60min
	<u>Neuronal</u> <u>cells</u> 70, 71	351.12	0.19			
	<u>Neuronal</u> <u>cells:</u> 108, 71	233.10	1.53			
	<u>Neuronal</u> <u>cells:</u> 98, 75	214.05	3.34			
	<u>Neuronal</u> <u>cells:</u> 91, 95	396.96	4.14			
	<u>Neuronal</u> <u>cells:</u> 100, 94	302.95	3.69			
	<u>Neuronal</u> <u>cells:</u> 94, 85	179.61	2.91			







- 44 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10 μ M) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells</u> 98, 58	159.19	2.58			
		243.24	-0.71			
		205.17	3.00			
	<u>Neuronal cells</u> 95, 48	160.18	1.75			
		189.17				
		189.17	2.67			
	<u>Neuronal cells</u> 94, 97	170.17	1.95			







- 45 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells:</u> 86, 85	173.22	3.03			
	<u>Neuronal cells:</u> 100, 75	263.30	3.70			
	<u>Neuronal cells</u> 89, 86	265.31	3.86			
		406.53	6.67			
	<u>Neuronal cells:</u> 100, 97	300.16	4.67			
	<u>Neuronal cells</u> 93, 72	255.71	4.30			
	<u>Neuronal cells:</u> 97, 26	297.36	5.35			







- 46 -







	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells</u> 83, 71	285.73	4.23			
	<u>Neuronal cells</u> 92, 78	300.70	4.06			
	<u>Neuronal cells</u> 103, 75	273.70	4.45			
	<u>Neuronal cells</u> 90, 66	291.69	4.60			
	<u>Neuronal cells</u> 97, 31	285.73	4.23			
	<u>Neuronal cells</u> 96, 54	273.70	4.45			

- 47 -








	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells</u> 109, 99	283.72	3.67			
	<u>Neuronal cells</u> 98, 71	273.70	4.45			
	<u>Neuronal cells</u> 94, 85	298.77	4.50			
	<u>Neuronal cells</u> 93, 34	325.41	5.75			
	<u>Neuronal cells</u> 95, 95	336.14	4.97			
	<u>Neuronal cells</u> 100, 100	269.73	4.50			

- 48 -









	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10nM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells</u> 98, 73	269.73	4.80			
	<u>Neuronal cells</u> 91, 90	415.16	5.76			
	<u>Neuronal cells</u> 99, 38	361.18	5.06			
	<u>Neuronal cells</u> 100, 52	357.41	4.09			
	<u>Neuronal cells</u> 91, 35	377.18	4.23			
	<u>Neuronal cells</u> 96, 93	323.70	5.20			

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells</u> 92, 34	365.15	5.01			
	<u>Neuronal cells</u> 100, 70	271.71	3.14			
	<u>Neuronal cells</u> 100, 100	282.30	1.61			
	<u>Neuronal cells</u> 96, 85	279.30	2.38			
	<u>Neuronal cells</u> 95, 93	293.33	2.51			
	<u>Neuronal cells</u> 104, 92	280.29	3.26			






- 50 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal</u> <u>cells</u> 100, 100	271.30	2.47			
	<u>Neuronal</u> <u>cells</u> 94, 68	285.33	2.93			
	<u>Neuronal</u> <u>cells</u> 100, 100	298.30	1.70			
	<u>Neuronal</u> <u>cells</u> 100, 100	295.30	2.71			
	<u>Neuronal</u> <u>cells</u> 100, 89	246.22	1.70			
	<u>Neuronal</u> <u>cells</u> 106, 96	231.26	1.43			
		211.23	2.97			








- 51 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
		211.23	1.94			
	<u>Neuronal</u> <u>cells</u> 100, 89	216.24	0.20			
	<u>Neuronal</u> <u>cells</u> 100, 91	216.24	0.89			
	<u>Neuronal</u> <u>cells</u> 101, 97	174.20	1.03			
	<u>Neuronal</u> <u>cells</u> 100, 95	188.19	2.83			
	<u>Neuronal</u> <u>cells</u> 87, 32	311.79	5.55			
	<u>Neuronal</u> <u>cells</u> 97, 84	357.2	4.57			
	<u>Neuronal</u> <u>cells</u> 93, 31	261.73	3.95			








- 52 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	Neuronal cells 90, 42	291.69	4.60			
		433.36	7.17			
		333.34	5.67			
		187.20	2.35			
	Neuronal cells 98, 82	295.30	2.80			








- 53 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells</u> 98, 89	355.36	1.08			
	<u>Neuronal cells</u> 93, 93	352.35	1.76			
	<u>Neuronal cells</u> 101, 43	268.32	1.14			
	<u>Neuronal cells</u> 97, 57	293.37	2.51			
	<u>Neuronal cells</u> 96, 67	265.32	1.11			
	<u>Neuronal cells</u> 98, 94	262.22	2.03			
	<u>Neuronal cells</u> 104, 96	225.25	2.21			







- 54 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells</u> 102, 97	212.21	1.75			
	<u>Neuronal cells</u> 82, 34	365.46	1.95			
	<u>Neuronal cells</u> 97, 38	362.46	2.19			
		293.33	4.70			
	<u>Neuronal cells</u> 114, 112	267.35	4.77			
	<u>Neuronal cells</u> 107, 75	222.25	3.00			
	<u>Neuronal cells</u> 91, 58	236.28	3.50			







- 55 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	Neuronal cells 97, 26	348.41	1.20			
	Neuronal cells 98, 27	359.43	1.88			
	Neuronal cells 87, 23	356.43	2.35			
	Neuronal cells 90, 70	345.41	1.68			
		285.33	2.22			
	Neuronal cells 81, 79	370.41	1.94			
	Neuronal cells 93, 89	202.21	0.89			








- 56 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
		202.21	1.72			
		188.19	1.60			
	<u>Neuronal cells</u> 91, 70	257.08	4.10			
	<u>Neuronal cells</u> 77, 54	271.10	3.27			
	<u>Neuronal cells:</u> 84, 72 <u>M17 cells:</u> 94, 54.3	271.1 36.36	3.51 (C) 1.07	None	Up to 500 ng/ml	12.85 at 5min, 9.45 at 60min
		163.15	2.34			







- 57 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
		318.36	1.75			
		361.20	2.54			
	<u>Neuronal cells</u> 74, 86	257.08	2.78			
	<u>Neuronal cells</u> 91, 84	351.19	2.79		Up to 2694ng/mL	
	<u>Neuronal cells</u> 88, 80	258.06	3.84			
		146.15				







- 58 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
		180.25				
		220.19				
		243.09	3.82			
		162.15				
	<u>Neuronal cells:</u> 101, 89					
	<u>Neuronal cells:</u> 93, 88 <u>M17 cells:</u> 108.3, 82.6	365.2 80	2.56	10 days, none	Up to 11605ng/mL	0.06 at 5min, 0.20 at 60min
	<u>Neuronal cells:</u> 87, 56 <u>M17 cells:</u> 78.3, 44	307.6 44.6	3.58	10 days, none	Up to 403ng/mL	







- 59 -







	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells:</u> 55, 31	291.14	4.21			
	<u>Neuronal cells:</u> 104, 98 <u>M17 cells:</u> 112, 93.7	231.3 58.	1.99 (E) 1.45	10 days, mild toxic signs	Below 80ng/mL in Tg mice	
		341.58				
	<u>Neuronal cells:</u> 98, 67 <u>M17 cells</u> 93.2, 47.3	325.1 52.9	3.33 (E) 5.32	5 days, none	Up to 120ng/mL in Tg mice	
	<u>Neuronal cells:</u> 100, 59	320.18	4.51			
	<u>Neuronal cells:</u> 101, 84	256.69	3.00			







- 60 -








	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells:</u> 82, 55	248.50	4.07			
		204.19	1.48			
	<u>Neuronal cells:</u> 94, 10	229.07	3.02			
	<u>Neuronal cells:</u> 91, 77 <u>M17 cells</u> 105.3, 72	271.1 52.9	2.11 (C) 1.33 (C) _{2.0} 1.41	10 days, none	Up to 5000ng/mL	0.26 at 5min, 0.24 at 60 min
		330.22	1.49			
	<u>Neuronal cells:</u> 41, 33	398.6 52.9	3.41	10 days, mild toxic signs	Up to 450ng/mL	

- 61 -









	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal</u> cells: 100, 93	229.1	3.24			
	<u>Neuronal</u> cells: 94, 87	229.1	3.24			
	<u>Neuronal</u> cells: 106, 93	272.1 49.3	2.57 (C) 0.37		Up to 1000 ng/mL	
	<u>Neuronal</u> cells: 100,93	231.0 61.7	1.66 (C) 0.84	3 days, none	Below 100ng/mL (single dose)	
	<u>Neuronal</u> cells: 97, 42 <u>M17 cells:</u> 41.2, 25.8	272.7	2.62			
		340.35	3.49			








	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
		215.25	2.97			
	<u>Neuronal cells:</u> 100, 98	186.1 46.0	2.22	6 days, none	Up to 350ng/mL (single dose)	
	<u>Neuronal cells:</u> 104, 91 <u>M17 cells:</u> 103.6, 101.3	328.2 58.4	2.58	14 days, 1 of 4 death	Up to 520ng/mL (single dose)	
	<u>Neuronal cells:</u> 116, 105 <u>M17 cells</u> 96.2, 76.8	285.1 52.9	2.74	11 days, none	Up to 2698ng/mL	0.12 at 5min, 0.07 at 60min
	<u>Neuronal cells:</u> 99, 98 <u>M17 cells</u> 101.9, 98.9	322.2 65.79	2.03	10 days, none	Up to 984ng/mL	0.16 at 5min, 0.10 at 60min
 .2HBr	<u>Neuronal cells:</u> 105, 94	342.2 58.4	2.87	10 days, none	Up to 262ng/mL in mice (single dose)	

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells:</u> 98, 81	344.2 67.6	1.92	10 days, none	Up to 10ng/mL (single dose)	
	<u>Neuronal cells:</u> 105, 70 <u>M17 cells:</u> 95.9, 80.9	316.1	1.84	10 days, none	Up to 45.2ng/mL	
	<u>Neuronal cells:</u> 96, 91	329.2	2.41	10 days, none	Up to 207ng/mL	
	<u>Neuronal cells:</u> 94, 70	328.2	2.10	10 days, mild signs		
	<u>Neuronal cells:</u> 105, 97 <u>M17 cells:</u> 106.9, 94.9	361.2	2.67	10 days, none	Up to 112.4ng/mL	
	<u>Neuronal cells:</u> 100, 93 <u>M17 cells</u> 97, 95.7	342.2 94.03	2.37	10 days, none	Up to 2439ng/mL	0.10 at 5min, 0.10 at 60min








	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells:</u> 99, 72 <u>M17 cells</u> 104.3, 76	340.2 78.9	1.95	10 days, none	Up to 3644ng/mL	0.18 at 5min, 0.08 at 60min
	<u>Neuronal cells:</u> 98, 51 <u>M17 cells</u> 87.9, 72.7	314.2	2.94	10 days, none		
	<u>Neuronal cells:</u> 94, 58 <u>M17cells</u> 86.9, 70.5	342.6	2.53	10 days, none		
	<u>Neuronal cells:</u> 102, 94	325.2	1.94	10 days, none	Up to 3896ng/mL	
	<u>Neuronal cells:</u> 96, 83	322.2	2.31	10 days, none	Up to 39ng/mL	
	<u>Neuronal cells:</u> 101, 88	300.1	2.38	10 days, none		
	<u>Neuronal cells:</u> 100, 92	336.2	2.36	10 days, none	Up to 59ng/mL	

- 65 -









	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal</u> cells: 95, 81 <u>M17 cells</u> : 100.9, 80.5	308.1	1.81	10 days, none	Up to 142.9 ng/mL (single dose)	
	<u>Neuronal</u> cells: 122, 93	338.2	2.58	10 days, none	Up to 80ng/mL (single dose)	
	<u>Neuronal</u> cells: 97, 96	328.2	1.99			
	<u>Neuronal</u> cells: 110, 102	316.2	2.19			
	<u>Neuronal</u> cells: 99, 93					
	<u>Neuronal</u> cells: 102, 83 <u>M17cells</u> 106.7, 98.8	273.12	2.82	10 days, none	Up to 2641ng/mL	
	<u>Neuronal</u> cells: 99, 88	336.2	2.48	10 days, 3/4 mild signs	Up to 439ng/mL	
	<u>Neuronal</u> cells: 103, 101 <u>M17cells</u> 112.7, 103.6	246.0	2.50			









	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal</u> <u>cells:</u> 100, 92 <u>M17cells</u> 105.1, 83.1	358.1	3.13	10 days, none	Up to 1,130.6 ng/mL	
	<u>Neuronal</u> <u>cells:</u> 89, 67 <u>M17cells</u> 94.9, 26.8	565.2	3.42	10 days, none		
	<u>Neuronal</u> <u>cells:</u> 86, 78	293.58	2.71			
	<u>Neuronal</u> <u>cells:</u> 100, 80	279.55	2.29			
	<u>Neuronal</u> <u>cells:</u> 74, 70	335.66	4.23			
	<u>Neuronal</u> <u>cells:</u> 99, 70 <u>M17cells</u> 101.8, 75.6	287.1	3.22	10 days, none	Up to 1802ng/mL	
	<u>Neuronal</u> <u>cells:</u> 104, 71 <u>M17cells</u> 94.3, 74.5	273.1	2.60	10 days, none	Up to 383ng/mL	

- 67 -










	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells:</u> 107, 96 <u>M17 cells</u> 115.3, 118.7	275.1	1.23	10 days, none	Up to 8134.8ng/mL	
	<u>Neuronal cells:</u> 107, 77 <u>M17 cells:</u> 100.5, 70.3	330.2	3.24	10 days, none	Up to 113.2 ng/mL (single dose)	
	<u>Neuronal cells:</u> 104, 85 <u>M17 cells</u> 105.4, 95.4	287.1	3.35			
	<u>Neuronal cells:</u> 94, 67 <u>M17 cells</u> 99.2, 68.6	287.1	3.13	10 days, none	Up to 2949ng/mL	
	<u>Neuronal cells:</u> 97, 90	269.3	1.76			
	<u>Neuronal cells:</u> 101, 73	366.0	3.35			
	<u>Neuronal cells:</u> 93, 58 <u>M17 cells</u> 104.3, 95.9	259.1	2.29			









- 68 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>Neuronal cells:</u> 103, 92	246.3	3.02			
	<u>M17 cells</u> 109.2, 96	253.3	0.87			
	<u>M17 cells</u> 103.9, 110.8	216.2	1.58			
		330.1	2.48	10 days, none	Up to 1096ng/mL (single dose)	
	<u>M17 cells</u> 110.9, 65.1	342.1 52.9	2.40	10 days, none	Up to 2508ng/mL	0.07 at 5min, 0.06 at 60min
		190.2	1.13			
	<u>M17 cells:</u> 93.8, 84.5	379.2	1.69	10 days, none	Up to 1538ng/mL	
		316.1	1.95	10 days, none		










	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>M17 cells</u> 96.1, 27.1	190.2	0.84			
		262.3	3.92			
		285.1	3.07			
	<u>M17 cells</u> 82.5, 23.3	316.1	1.63	<u>At</u> <u>10mg/kg</u> 10 days, none	<u>At 10mg/kg:</u> Up to 7082ng/mL	
	<u>M17 cells</u> 106.5, 99.1	316.2	2.55	10 days, none	Up to 2289ng/mL	
		234.2	0.35			
	<u>M17 cells</u> 100.6, 85.4	224.6	1.89			
	<u>M17 cells</u> 89.4, 79.4	238.7	2.42			

- 70 -









	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	M17 cells: 86.3, 57.6	250.7	2.34			
	M17 cells 93.6, 88.4	287.7	1.63			
	M17 cells: 117.1, 105.6	427.4	1.10	10 days, none	Up to 128.4ng/mL	
	M17 cells 99.7, 45.6	204.2	1.24	10 days, none	Up to 409ng/ml	
	M17 cells: 84.4, 92.1	245.3	2.56		Up to 125.5 ng/mL (Single dose)	
	M17 cells: 100.8, 50.4	350.5	2.68	10 days, 2/4 deaths	Up to 1802ng/mL	
	M17 cells: 120.2, 100.2	364.6	3.21		Up to 4060ng/mL	
	M17 cells: 97.9, 82.3	376.6	3.13	At 10mg/kg: 10 days, none		
	M17 cells: 102.2, 99.2	413.6	2.42			

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>M17 cells:</u> 96.7, 44.2	330.12	2.03	10 days, 1/4 death, remaining 1/3 mild sings		
	<u>M17 cells:</u> 93.3, 73.7	206.27	1.66			
	<u>M17 cells:</u> 73.6, 37	218.25	1.90	10 days, none		
	<u>M17 cells:</u> 101.7, 58.7	344.15	2.69	10 days, 2/4 deaths		
	<u>M17 cells</u> 97.4, 100.3	288.13	1.50	10 days, none	Up to 642.6ng/mL	
		234.32	2.72	7 days, 2/4 deaths	Up to 57ng/ml	
	<u>M17 cells</u> 79.1, 45.2	204.23	1.37	10 days, none	Up to 690ng/ml	
	<u>M17 cells</u> 80.8, 47.6	330.12 52.9	2.16	10 days, none	Up to 11742ng/ml	0.02 at 5min, 0.03 at 60min









- 72 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>M17 cells:</u> 111.2, 68.2	344.15	2.88	<u>At</u> <u>10mg/kg:</u> 10 days, none	<u>At 10mg/kg:</u> Up to 309ng/ml	
		330.12	2.26	10 days, 1/4 deaths	Up to 277ng/ml	
	<u>M17 cells:</u> 76.7, 54.2	313.28	1.31			
		679.21	2.74			
	<u>M17 cells</u> 92.7, 67.5	256.23	2.19			
	<u>M17 cells:</u> 90.3, 80.3	400.12	3.15	6 days, 2/4 deaths		
	<u>M17 cells:</u> 89.6, 23.4	439.18	2.09	7 days, 4/4 deaths		
	<u>M17 cells</u> 98.8, 48.4	261.28	0.78			
	<u>M17 cells</u> 85.3, 63.4	387.17	1.56	10 days, none	Up to 27,598ng/ml	









- 73 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	M17 cells 96, 90.6	288.13	1.13	10 days, none	Up to 510.4 ng/mL	
	M17 cells: 94.6, 30.2	382.13	2.99			
	M17 cells: 106.5, 41.4	387.22	2.90			
	M17 cells: 97.4, 95	399.57	2.20			
	M17 cells 89.9, 86.2	346.19	3.65	10 days, none	Up to 1593ng/ml	
	M17 cells: 84.3, 95.5	387.17	1.81			
	M17 cells: 92.2, 98.7	401.2	2.24			
	M17 cells 85.7, 43	332.2	3.12	10 days, none, 1/4 mild signs	Up to 400ng/ml	







- 74 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10nM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
		442.0	3.09			
	M17 cells: 127.4, 104.8	461.2	2.76			
	M17 cells: 60.1, 34.2	356.34	1.45			
 .HBr		166.20	1.93			
	M17 cells: 86.3, 38.5	358.18	3.53			
	M17 cells: 97.9, 24.4	362.60	3.56	1 day, 3/4 deaths		
	M17 cells 110.1, 98.2	269.28	1.12			
		352.37	2.62			








- 75 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	M17 cells 102.7, 47.2	232.28	2.59			
	M17 cells 103.9, 106.5	335.31	1.94			
		331.11	0.97			
	M17 cells: 42.8, 19.3	358.18	3.41			
	M17 cells 118.3, 102.1	275.30	1.42			
	M17 cells 102.1, 32.84	332.31	1.27			
	M17 cells 115.2, 102.7	304.34	0.66			
	M17 cells 81.3, 56.8	301.17	3.88			








- 76 -









	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	M17 cells 85.1, 39.4	301.17	3.75			
	M17 cells 99.1, 73.7	313.31	2.21			
	M17 cells 104.5, 103.7	274.22	2.34			
	M17 cells 99.4, 67.1	317.25	0.68			
	M17 cells: 106.9, 122.1	273.67	1.40	10 days, none	Up to 6ng/mL	
	M17 cells: 98.5, 90.4	252.27	2.37			Not novel

- 77 -










	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>M17 cells:</u> 92.7, 97.3	295.29	1.16	10 days, none	Up to 22.2ng/mL	
	<u>M17 cells</u> 107, 108.5	292.29	1.79			
	<u>M17 cells:</u> 96.5, 43	489.26	3.05			
	<u>M17 cells:</u> 103.7, 98.6,	437.25	2.04			
	<u>M17 cells</u> 106.1, 27.24	308.42	2.36			
	<u>M17 cells</u> 103.8, 101.1	404.20	3.10			
	<u>M17 cells</u> 75.3, 33.8	256.23	2.05			

- 78 -









	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>M17 cells</u> 105.5, 109.7	239.23	0.68			
	<u>M17 cells</u> 102.5, 102.6	307.26	1.15			
	<u>M17 cells</u> 97.8, 109.7	269.26	1.45			
	<u>M17 cells</u> 104.7, 103.5	253.26	0.87			
	<u>M17 cells</u> 107, 96.2	267.29	1.20			
	<u>M17 cells</u> 108.2, 103.4	278.27	1.62			
	<u>M17 cells</u> 100.9, 37.9	312.34	3.43			










	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>M17 cells</u> 79.2, 64.4	324.37	3.21			
	<u>M17 cells</u> 92.1, 38.2	295.34	1.80			
	<u>M17 cells</u> 95, 98.4	292.29	1.44			
	<u>M17 cells</u> 97.2, 60.5	270.26	2.51			
	<u>M17 cells</u> 94.5, 59.1					
	<u>M17 cells</u> 98.1, 38.9					
	<u>M17 cells</u> 109.2, 98.2	361.18	2.60	10 days, none	Up to 98.3ng/mL	
	<u>M17 cells</u> 105.7, 95.4	322.15	2.03	10 days, none	Up to 4023.4ng/mL	

- 80 -





	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>M17 cells</u> 105.4, 90.4	322.15	2.03	10 days, none	Up to 2181.1ng/mL	
	<u>M17 cells</u> 107.8, 89.2	308.12	1.81	10 days, none	Up to 144.2ng/mL	
	<u>M17 cells</u> 107.5, 97.6	325.15	1.34	10 days, none	Up to 13214.8ng/mL	
	<u>M17 cells</u> 125.7, 114.8	297.10	1.69	10 days, none	Up to 1477.4ng/mL	
	<u>M17 cells</u> 82.7, 63.9	364.21	3.197			
	<u>M17 cells</u> 96.2, 88.9	347.16	2.78	10 days, none	Up to 126ng/mL	
	<u>M17 cells</u> 85.4, 93.3	376.15	2.297	10 days, none		
	<u>M17 cells</u> 93, 98	414.26	1.79			
	<u>M17 cells</u> 105, 100.7	289.08	1.63	10 days, none		

- 81 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	M17 cells 95.1, 93.9	337.17	1.71	10 days, 1 of 4 deaths		
	M17 cells 102.8, 62.1	376.25	3.24			
	M17 cells 105.4, 105.1	361.18	2.60	10 days, none	Up to 1465.4ng/mL	
	M17 cells 106.6, 93.9	328.20	2.57	10 days, none	Up to 382.5ng/mL	
	M17 cells 96, 99.8	328.17	1.88	10 days, none	Up to 441.4ng/mL	
	M17 cells 109.7, 102.9	317.12	1.92	10 days, none	Up to 17008ng/mL	
	M17 cells 101.5, 100.4	361.18	2.95	10 days, none	Up to 2796ng/mL	
	M17 cells 111.1, 80.9	378.23	3.47	10 days, none	Up to 166.1ng/mL	

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (% viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	<u>M17 cells</u> 115.1, 93.9	271.1	2.28			
	<u>M17 cells</u> 109.1, 83.4	418.23	4.23			
	<u>M17 cells</u> 122.3, 104.1	344.19	2.58			
	<u>M17 cells</u> 100, 106.9	302.16 64.9	2.12			
	<u>M17 cells</u> 106.5, 94.2	326.14	1.84	10 days, none	Up to 7107ng/mL	
	<u>M17 cells</u> 103, 104.8	365.21	2.02	10 days, none	Up to 1639.8ng/mL	
	<u>M17 cells</u> 98.8, 96.2	314.17	1.95			
	<u>M17 cells</u> 99.6, 95.4	326.13	1.79			
	<u>M17 cells</u> 94.4, 74.5	342.22	2.57	10 days, none	Up to 1166.6ng/mL	

- 83 -

	In vivo Efficacy and Safety Profile					
	Cytotoxicity (%viable at 1 and 10uM) ^a	Parent MW/ PSA	ClogP ElogD (E) or ClogD (C)	Toxicity ^b at 30mg/kg	Mice plasma concentration ^c	B:P Ratio ^d
	M17 cells 99.2, 102.1	316.18	2.13	10 days, none	Up to 975.9ng/mL	
	M17 cells 104, 110.7	302.156	1.60	10 days, 1 of 4 mild signs	Up to 492.1ng/mL	/
	M17 cells 104.4, 61.5	344.34	.			
	M17 cells 100.6, 114.7	176.18	.			

a- Viability of primary cortical neuronal cultured cells (Neuronal cells) or M17 human neuroblastoma cells (M17 cells) in the presence of test compound at concentrations of 1 and 10 μ M.

b- Visual observations

c- Confirmation of presence of compound in plasma at one or two time points (between 30 min and 4h) Brain uptake of test compound following IV administration to male Swiss Outbred mice at a nominal dose of 5mg/kg. Results are expressed as the brain:plasma ratio at 5min and 60min post dose.

5

10

- 84 -

EXAMPLE 3***Testing compounds for in vitro and in vivo efficacy***

Twelve compounds were screened for *in vitro* efficacy and 4 were tested for *in vivo* efficacy.

Emulsion carrier was used as a control for the *in vitro* and *in vivo* test systems. All the compounds were tested initially via *in vitro* testing to determine an efficacy profile with three glioma cell lines and a control cell line. The results are shown in Figs. 2 to 5.

Experimental Design***In vitro efficacy Protocol***

The *in vitro* efficacy of the test articles were analyzed *via* the MTT cell viability assay.

The following cell lines were used to determine cell viability on exposure to the test articles : C6 – rat glioma cell line (Figure 1), VMDK – mouse glioma cell line (Fig. 3), U87MG – human glioma cell line (Figure 2), 3T3 - Control cell line (Fig. 4).

Cells were plated in 96 well plates with 100 µl of cell culture medium and be allowed to adhere over 24 hours allowing for approximately 50 % confluence. At 24 hours, the cell medium was replaced with fresh cell culture medium containing compounds or the carrier emulsions.

The cells will then be incubated and grown for a designated period (72 hours) after which the MTT solution were added to the wells and incubated at 37°C for 1-2 hours. The absorbance of each well will then be measured with a plate reader at 570 nm. The efficacy profiles were calculated relevant to the cells incubated in the absence of the compounds over the course of the experiment.

In vivo efficacy protocol

5 2 doses were used: at the maximum tolerated dose and one level below the maximum tolerated dose.

3 mouse models are employed:

- C6 – xenograft mouse model (glioma model)
- 10 • SMA560 – VMDK mouse model (glioma model)
- U87MG – nude mouse model

C6 – CBA Xenograft model (ATCC Number: CCL-107)

15 This model is used to screen 4 compounds.

SMA560 – VMDK mouse model (ATCC Number: CCL-163)

20 This model is used to screen the 4 compounds screened previously with the C6 xenograft model.

U87MG Nude mouse model (ATCC Number: CRL-9589)

This model is used to screen 2 compounds.

25

Initially, CBA mice are used to receive an intracranial inoculation of the C6 glioma cells. Briefly, 1×10^6 cells are inoculated into the left hemisphere *via* at day 5 post C6 cell inoculation. The mice receive daily intraperitoneal (ip) administration of test articles in a carrier emulsion or carrier emulsion alone as a control for 8 days until day 12. At day 14,
30 the mice are euthanised *via* CO₂ inhalation and the brain removed for histological processing.

- 86 -

The VMDK mouse strain is then used to screen the identical test articles and carrier emulsions as per the C6 xenograft model in the CBA mice. The VMDK mice received an inoculation of 1×10^5 SMA560 cells into the left hemisphere *via* standard methods. At day 5 post SMA560 cell inoculation, the mice receive daily ip administration of agents in a carrier emulsion or carrier emulsion alone as a control for 12 days until day 16. Identical doses of test articles and carrier emulsions as used in the C6 xenograft model are used with the SMA560 model. At day 18, the mice are euthanized *via* CO₂ inhalation and the brain removed for histological processing.

A nude mouse model utilizing the U87MG human glioma cell line is used to screen agents. The nude mouse Nu/nu strain receives an inoculation of 1×10^6 U87MG cells into the left hemisphere. At day 5 post U87MG cell inoculation, the mice receive daily ip administration of the agent or carrier emulsion alone as a control for 12 days until day 16. At day 18, the mice are euthanized *via* CO₂ inhalation and the brain removed for histological processing.

Haematoxylin and eosin stained sections are used to measure tumor dimensions in order to determine the efficacy of the test compounds on tumor growth relative to the control mice.

The results of the effects of compounds A, B, S and H are shown in Figs. 6a to d.

The graphs can be summarized as follows:

Y-axis refers to the tumor area in pixels.

The numbers in the bars refer to the total mice in each group (mice that were found dead very early or brains could not be sampled due to the head being chewed by other mice were not included).

The numbers with the asterix refer to the groups where mice may have been culled 1 or 2 days early due to being ill or found dead. These have been included in the final

- 87 -

calculations as their tumors were fairly large and were they were culled close to the final cull point.

Example 4

Clinical Development of Compound B

Compound B was administered to healthy volunteers in a 2-part study comprising single dose administration (Stage A) and multidose administration (Stage B). Overall, Compound B was generally well tolerated as a single dose in young male volunteers and up to 7 days of treatment in elderly healthy volunteers.

The objectives of the Phase I trials were to determine the safety, tolerability and pharmacokinetics of single and multiple oral doses of Compound B in healthy volunteers. The double-blind studies were conducted at a Phase I unit in The Netherlands. The protocol included safety measures designed to capture the potential human adverse effects.

A total of 65 healthy subjects have been exposed to doses of Compound B (41 single dose, 24 multiple dose).

Disposition of Subjects – Stages A & B

Stage	Sex	Number of Subjects (N)										Total	
		Placebo	Compound B (mg)										
			25	50	100	200	300	400	500	600	800		
A	M	14	5	6	6	6	6	-	6	-	6	55	
B	M	4	-	-	-	3	-	3	-	3	3	16	
	F	4	-	-	-	3	-	3	-	3	3	16	
	Total	8	-	-	-	6	-	6	-	6	6	32	

Safety and Tolerability Stage A – Single Dose

In Stage A, fifty five (55) healthy male subjects aged 18-50 years were randomised (3:1) to receive a single oral dose of either placebo or Compound B at one of 7 dose levels (25, 50, 100, 200, 300, 500 or 800 mg).

Analysis from Stage A demonstrated that Compound B, when administered as a single oral dose, was well tolerated in healthy male volunteers aged 18 to 50 years. There was no difference in the incidence of adverse events between the Compound B (43.9%) and placebo arms (42.9%).

Safety and tolerability Stage B – Multiple dose

In Stage B, thirty two (32) healthy male and female subjects aged 45-75 years (eight subjects per dose level) were randomised (3:1) to receive a daily oral dose over 7 consecutive days of either placebo or Compound B at one of 4 dose levels (200, 400, 600 or 800 mg). Each dose level comprised of 4 males and 4 females; the randomisation schedule ensuring that 1 subject/sex received placebo and 3 subjects/sex received Compound B.

Analysis of Stage B indicates that Compound B was generally well tolerated in healthy elderly subjects.

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word “comprise” or variations such as “comprises” or “comprising” is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

Bevan and Lloyd, *Anal. Chem.* 72:1781-1787, 2000

Goodman and Gilman's, *The Pharmacological Basis for Therapeutics 7th ed.*, 1985

Lombardo *et al*, *J. Med. Chem.* 43:2922-2928, 2000

Remington's Pharmaceutical Sciences, 20th ed. Williams and Wilkins, 2000

The British National Formulary 43rd ed., British Medical Association and Royal
Pharmaceutical Society of Great Britain, 2002


- 90 -

CLAIMS:

1. A method for the treatment, amelioration and/or prophylaxis of a glioma brain tumour which comprises administration of an effective amount of an agent which comprises a compound having two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxy at position 8 or a formulation comprising such an agent to a subject in need thereof.
2. The method of Claim 1 wherein the effective amount is a specific dosage amount.
3. The method of Claim 2 wherein the specific dosage amount is from about 200 to about 800 mg/subject.
4. The method of Claim 3 wherein the specific dosage amount is about 500 mg/subject.
5. The method of Claim 1 or 2 wherein the glioma brain tumour is selected from astrocytoma, glioblastoma multiforme (GBM), anaplastic astrocytoma, mixed glioma and oligodendroglioma.
6. The method of Claim 5 wherein the glioma is astrocytoma.
7. The method of Claim 5 wherein the glioma is GBM.
8. The method of Claim 5 wherein the glioma is anaplastic astrocytoma.

- 91 -

9. The method of any one of Claims 1 to 8 wherein the agent comprises a compound of formula (I):



(I)

in which

R^2 is H; optionally substituted C_{1-6} alkyl; optionally substituted C_{2-6} alkenyl; optionally substituted C_{2-6} alkynyl; optionally substituted C_{3-6} cycloalkyl; optionally substituted aryl; optionally substituted heterocyclyl; CN; OR^6 , SR^6 , COR^6 , CSR^6 , $HCNOR^6$ or $HCNNR^6$ in which R^6 is H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; NR^8R^9 or $SO_2NR^8R^9$ in which R^8 and R^9 are independently selected from H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl and optionally substituted heterocyclyl; $CONR^9R^{10}$ in which R^9 is as defined above and R^{10} is optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; $CH_2CONR^8R^9$ in which R^8 and R^9 are as defined above; and $(CH_2)NR^9R^{11}$ in which R^9 is as defined above and R^{11} is selected from optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and SO_2R^{12} in which R^{12} is optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl and n is 1 to 6;

R^3 is independently selected from H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6}

- 92 -

cycloalkyl, optionally substituted aryl, optionally substituted heterocycyl; optionally substituted C₁₋₆ alkoxy, optionally substituted acyl, hydroxy, optionally substituted amino, optionally substituted thio, optionally substituted sulphonyl, optionally substituted sulphinyl, optionally substituted sulphonylamino, halo, SO₃H, amine, CN, CF₃ and halo;


X is CH or N;

Y is CH, CO, CS or N; and

q is 1, 2 or 3,

salts, hydrates, solvates, derivatives, pro-drugs, tautomers and/or isomers thereof.

10. The method of claim 9 wherein the compound of formula (I) has the formula (I')



in which

R² is H; optionally substituted C₁₋₆ alkyl; optionally substituted C₂₋₆ alkenyl; optionally substituted C₂₋₆ alkynyl; optionally substituted C₃₋₆ cycloalkyl; optionally substituted aryl; optionally substituted heterocycyl; CN; OR⁶, SR⁶, COR⁶, CSR⁶, HCNOR⁶ or HCNNR⁶ in which R⁶ is H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl or optionally substituted heterocycyl; NR⁸R⁹ or SO₂NR⁸R⁹ in which R⁸ and R⁹ are independently selected from H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl and optionally substituted heterocycyl; CONR⁹R¹⁰ in which R⁹ is as defined above and R¹⁰ is optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₆ cycloalkyl, optionally substituted aryl or optionally substituted heterocycyl; CH₂CONR⁸R⁹ in which R⁸ and R⁹ are as defined above; and (CH₂)NR⁹R¹¹ in

- 93 -

which R^9 is as defined above and R^{11} is selected from optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and SO_2R^{12} in which R^{12} is optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl and n is 1 to 6;




R^5 and R^7 are independently selected from H, optionally substituted C_{1-6} alkyl and halo;

X is CH or N;



Y is CH, CO, CS or N; and

q is 1, 2 or 3.

11. The method of Claim 10 wherein the compound of formula (I') is selected from the group consisting of compounds of the formulae (IA) to (IE):




- 94 -




in which

R^2 , R^5 , R^7 and q are as defined in claim 9, and r is 1 or 2.

12. The method of Claim 10 wherein the compound of formula (I') is selected from the group consisting of compounds A to ZA as follows:




Compound A




Compound B


- 95 -




Compound C




Compound D




Compound E



Compound F




Compound G




Compound H


- 96 -




Compound I




Compound J




Compound K




Compound L



Compound M




Compound N




Compound O


- 97 -




Compound P




Compound Q




Compound R




Compound S



Compound T




Compound U




Compound V


- 98 -




Compound W



Compound X



Compound Y



Compound ZA



13. Use of an agent which comprises a compound having at least two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8 for the manufacture of a medicament of the treatment, amelioration and/or prophylaxis of a glioma brain tumour.
14. Use of Claim 13 wherein the medicament is a specific dosage amount.
15. Use of Claim 14 wherein the specific dosage amount is from about 200 to about 800 mg/subject.
16. Use of Claim 15 wherein the specific dosage amount is about 500 mg/subject.
17. Use of Claim 13 wherein the glioma brain tumour is selected from astrocytoma, GBM, anaplastic astrocytoma, mixed glioma and oligodendroglioma.
18. Use of Claim 17 wherein the glioma is astrocytoma.



- 99 -





19. Use of Claim 17 wherein the glioma is GBM.
20. Use of Claim 17 wherein the glioma is anaplastic astrocytoma.
21. Use of any one of Claims 13 to 20 wherein the agent comprises the compound of formula (I) according to claim 9.
22. Use of claim 21 wherein the compound of formula (I) has the formula (I') according to claim 10.
23. Use of Claim 22 wherein the compound of formula (I') is selected from the group consisting of compounds of the the formulae (IA) to (IE) according to claim 11.
24. Use of Claim 22 wherein the compound of formula (I) is selected from the group consisting of compounds A to ZA according to claim 12.
25. A formulation comprising an agent which comprises a compound having two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8 for treating, ameliorating and/or preventing a glioma brain tumour.
26. A formulation comprising an agent which comprises the compound of formula (I) according to claim 9 for treating, ameliorating and/or preventing a glioma brain tumour.
27. The formulation of claim 26 wherein the compound of formula (I) has the formula (I') according to claim 10.
28. The formulation of Claim 27 wherein the compound of formula (I') is selected from the group consisting of compounds of the formulae (IA) to (IE) according to claim 12.
29. The formulation of Claim 27 wherein the compound of formula (I) is selected from the group consisting of compounds A to ZA according to claim 12.

- 100 -

30. The formulation of any one of Claims 25 to 29 further comprising another active agent.
31. The formulation of Claim 30 wherein the further active agent is selected from a chemotherapeutic compound, cytokine and an anesthetic.
32. The formulation of Claim 31 wherein the chemotherapeutic compound is selected from a chemical compound, immunological compound, natural product or sRNAi complex or a product of an introduced viral vector.

Compound A**Compound N****Fig. 1**

Compound I**Compound O****Fig. 1 cont.**

Compound U**Compound X****Fig. 1 cont.**






Fig. 2

**Fig. 3**

**Fig. 4**








Fig. 5

a**b****Fig. 6a-b**

c**d****Fig. 6c-d**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2007/000876

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl.		
C07D 215/28 (2006.01)	C07D 241/42 (2006.01)	C07D 239/88 (2006.01)
A61K 31/517 (2006.01)	A61P 35/04 (2007.01)	A61K 31/47 (2006.01)
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CA, WPIDS and Medline. Structure and keywords: Brain tumour, Glioma, Astrocytoma, Glioblastoma and related terms.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO2005063213 A1 (BIODELIVERY SCIENCES INTERNATIONAL INC.) 14 July 2005. See page 1 lines 10-23, Claims 14-17 and 35.	1-32
X	WO2003072578 A1 (PHARMACIA & UPJOHN CO.) 4 September 2003. See Abstract, pages 6-7, 10-11, 18, 36, 43, 97, 100, Example 8, Claims 22-23, 41	1-11, 13-23, 25-28.
P,X	CHEN, D. et al. Clioquinol, A Therapeutic Agent for Alzheimer's Disease, has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts. Cancer Res. Feb 2007, Vol. 67, No. 4, pages 1636-1644. See Abstract and Fig 1.	1-29
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"p"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 13 August 2007		Date of mailing of the international search report 16 AUG 2007
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer Tseng Lau AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No : (02) 6225 6110

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2007/000876

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BANDYOPADHYAY, S. et al. Metal Specificity of an Iron-Responsive Element in Alzheimer's APP mRNA 5'Untranslated Region, Tolerance of SH-SY5Y and H4 Neural Cells to Desferrioxamine, Clioquinol, VK-28, and a Piperazine Chelator. J. Neural Transm. Suppl., 2006, Vol. 71, pages 237-247. See page 242 left-hand column and Fig 3.	1-29
Y	DING, W-Q. et al. Anticancer Activity of the Antibiotic Clioquinol. Cancer Res. 2005, Vol. 65, No. 8, pages 3389-3395. See Abstract, page 3389 left-hand column.	1-29
Y	FAN, L. et al. Inhibition of N-Myc Expression and Induction of Apoptosis by Iron Chelation in Human Neuroblastoma Cells. Cancer Research, 2001, Vol. 61 pages 1073-1079. See Abstract.	1-29
P, X	WO2007064797 A2 (VERTEX PHARMACEUTICALS INC.) 7 June 2007. See pages 1, 2, Table 1 Compounds 352 and 454, paragraphs [0087-0090], Claim 21.	1-11, 13-23, 25-28, 30-32.
P,X	WO2007068316 A1 (MERCK PATENT GMBH) 21 June 2007. See whole document.	1-11, 13-23, 25-28, 30-32.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2007/000876

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-11
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
See Supplemental Box I for details.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2007/000876

Supplemental Box I

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

Present Claims 1-11 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search can be carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds listed in Claim 12 and disclosed in the description on pages 11-15, 17-24.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU2007/000876

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member				
WO	2007064797						
WO	2007068316	DE	1020050594				
WO	2005063213						
WO	03072578	AU	2003214936	BR	0307874	CA	2475773
		EP	1478646	MX	PA04007083	US	7001900
		US	2003236270				
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.							
END OF ANNEX							